Bio-Rad Laboratories Class B
BIO.B
8 hedge funds and large institutions have $15M invested in Bio-Rad Laboratories Class B in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
296% more capital invested
Capital invested by funds: $3.79M → $15M (+$11.2M)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
1.87% more ownership
Funds ownership: 0.58% → 2.45% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$11.7M |
| 2 |
Barclays
London,
United Kingdom
|
+$6.13K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$5.15K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$123 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
-$22.7K |
| 2 |
Citigroup
New York
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TM
1
Tikvah Management
Charlotte,
North Carolina
| $11.4M | +$11.7M | +95,197 | New |
|
|
CL
2
CSS LLC
Chicago,
Illinois
| $2.75M | – | – | – |
|
3
Dimensional Fund Advisors
Austin,
Texas
| $806K | – | – | – |
|
|
U
4
UBS
Zurich,
Switzerland
| $60K | -$22.7K | -185 | -27% |
|
5
Invesco
Atlanta,
Georgia
| $12K | – | – | – |
|
|
6
Barclays
London,
United Kingdom
| $9K | +$6.13K | +50 | +217% |
|
|
BIT
7
BlackRock Institutional Trust
San Francisco,
California
| $5K | +$5.15K | +42 | New |
|
|
8
Citigroup
New York
| – | -$11K | -86 | Closed |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | +$123 | +1 | +50% |
|
BIO.B Hedge Fund Activity: Q2 2014 in Review
8 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q2 2014, worth a combined $15M — up 296% from $3.79M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIO.B positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Tikvah Management, opening a new position worth an estimated $11.7M. The largest seller was UBS, cutting an estimated $22.7K.
- 8 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q2 2014, up from 7 in Q1 2014.
- Funds reported $15M of Bio-Rad Laboratories Class B stock for Q2 2014, up 296% quarter-over-quarter.
- 2 funds opened new Bio-Rad Laboratories Class B positions in Q2 2014 and 1 closed out, a net change of +1 holder.
- The largest Bio-Rad Laboratories Class B buyer in Q2 2014 was Tikvah Management, an estimated $11.7M added.
- The largest Bio-Rad Laboratories Class B seller in Q2 2014 was UBS, an estimated $22.7K sold.
Based on aggregated 13F filings for Q2 2014.